Literature DB >> 15698753

AOT water-in-oil microemulsions as a penetration enhancer in transdermal drug delivery of 5-fluorouracil.

Reeta R Gupta1, Swantrant K Jain, Manoj Varshney.   

Abstract

In vitro transdermal permeation of 5-fluorouracil (antineoplastic), a hydrophilic drug encapsulated in AOT/water/isopropylmyristate water-in-oil microemulsions (MEs), were studied using a modified Keshary and Chien diffusion cell. AOT (aerosol-OT or sodium bis(2-ethylhexyl) sulfosuccinate) is an anionic surfactant, which forms 'water-in-oil' ME in non-aqueous medium. The effect of water and AOT concentrations in MEs to the transdermal permeation of 5-fluorouracil through hairless mouse skin was investigated. MEs with 5:95 weight ratio of AOT:isopropylmyristate, containing 0.9, 1.8, 2.7 and 3.6% w/w of water have showed 1.68-, 2.36-, 3.58- and 3.77-fold increases in the skin flux of 5-fluorouracil (5-FU) respectively, compared to the aqueous solution of drug. The MEs with 5:95, 9:91 and 13:87 weight ratio of AOT:isopropyl myristate at fixed water content W0=15 (W0=[H2O]/AOT]) gave 3.58-, 5.04- and 6.3-fold enhancement of drug. In addition, attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy was used to examine the effect of ME on lipid alkyl chain, hydration level, and corneocyte cells of the stratum corneum (SC). Results reveal that the ME interacts with a component of the SC and perturbs its architectural structure. The extent of perturbation in the SC depends on the concentration of water and AOT in the ME. Preliminary dermal toxicity studies indicate that the AOT/water/isopropylmyristate ME be safe for the transdermal permeation of 5-FU.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698753     DOI: 10.1016/j.colsurfb.2004.09.008

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  8 in total

1.  Enhanced insulin absorption from sublingual microemulsions: effect of permeation enhancers.

Authors:  Nilam H Patil; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

2.  Transdermal delivery of an anti-cancer drug via w/o emulsions based on alkyl polyglycosides and lecithin: design, characterization, and in vivo evaluation of the possible irritation potential in rats.

Authors:  Aliaa Nabil ElMeshad; Mina Ibrahim Tadros
Journal:  AAPS PharmSciTech       Date:  2010-12-09       Impact factor: 3.246

3.  The effect of microneedles on the skin permeability and antitumor activity of topical 5-fluorouracil.

Authors:  Youssef W Naguib; Amit Kumar; Zhengrong Cui
Journal:  Acta Pharm Sin B       Date:  2014-02-01       Impact factor: 11.413

4.  Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil.

Authors:  Paruvathanahalli Siddalingam Rajinikanth; Jestin Chellian
Journal:  Int J Nanomedicine       Date:  2016-10-05

5.  A comparative ex vivo permeation evaluation of a novel 5-Fluorocuracil nanoemulsion-gel by topically applied in the different excised rat, goat, and cow skin.

Authors:  Niyaz Ahmad; Rizwan Ahmad; Taysser Mohammed Buheazaha; Hussain Salman AlHomoud; Hassan Ali Al-Nasif; Md Sarafroz
Journal:  Saudi J Biol Sci       Date:  2020-03-03       Impact factor: 4.219

6.  A novel 5-Fluorocuracil multiple-nanoemulsion used for the enhancement of oral bioavailability in the treatment of colorectal cancer.

Authors:  Niyaz Ahmad; Ahmed A Albassam; Mohd Faiyaz Khan; Zabih Ullah; Taysser Mohammed Buheazah; Hussain Salman AlHomoud; Hassan Ali Al-Nasif
Journal:  Saudi J Biol Sci       Date:  2022-03-14       Impact factor: 4.052

7.  Overcoming the cutaneous barrier with microemulsions.

Authors:  Luciana B Lopes
Journal:  Pharmaceutics       Date:  2014-02-28       Impact factor: 6.321

8.  Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation.

Authors:  Rudra Pangeni; Sang Won Choi; Ok-Cheol Jeon; Youngro Byun; Jin Woo Park
Journal:  Int J Nanomedicine       Date:  2016-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.